CTRI/2023/08/056267尚未招募4 期
A Prospective, Multi-center, Single-arm, Phase IV Study to Assess the Safety & Efficacy of Amoxycillin and Potassium Clavulanate Oral Suspension in Children With Upper Respiratory Tract Infection (URTI) or Lower Respiratory Tract Infection (LRTI) - NI
Sun Pharmaceuticals Industries Limited SPI0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Children of either gender, aged between =3 months and <18 years, and weight less than 40 kg
- •2.Confirmed clinical diagnosis of URTI [acute otitis media (AOM) OR tonsillo-pharyngitis OR acute bacterial sinusitis] OR LRTI [lobar pneumonia and/or bronchopneumonia] for which patient require treatment with Amoxycillin and Potassium Clavulanate Oral Suspension based on Investigator’s opinion
- •3.Parent/Legal guardian is willing to give written informed consent and patient willing to give oral assent if aged 7 to <12 years and written assent if aged =12 years
- •4.Patient able to swallow study medications and follow study protocol
- •5.For females of childbearing potential, parents should confirm that the patient is not pregnant and investigator should also confirm the same. In case of any doubt, investigator should conduct urine pregnancy test (UPT).
- •Note: However, if pregnancy is detected any time after enrolment, then parents should inform the investigator and the patient should be withdrawn from the study.
排除标准
- •1.Patients weighing >40 kg
- •2.Suspicion of non-infectious or viral aetiology
- •3.Patients with complicated URTI/ LRTI requiring intravenous antibiotics or hospitalisation
- •4.Patient with history of prior lung conditions
- •5.Patient with history of pulmonary tuberculosis
- •6.Patient having history of hypersensitivity to penicillin or any beta-lactam antibiotics
- •7.Patient having history of amoxycillin-clavulanate associated cholestatic jaundice/ hepatic impairment
- •8.Patient having history of bleeding disorder or currently on anticoagulants
- •9.Patient with history of phenylketonuria
- •10.Patient undergoing haemodialysis
- •11.Patients on probenecid or allopurinol
- •12.Patients with any clinically significant condition which in the opinion of Investigator would compromise the well-being of the patient or the conduct of the study, or prevent the patient from meeting or performing study requirements.
- •13.Patients with high risk of carrying amoxycillin-resistant organisms [received amoxycillin or penicillin or other beta-lactam antimicrobials in the last 30 days, OR history of methicillin-resistant Staphylococcus aureus (MRSA) infection]
- •14.Patient using other antimicrobials in last 30 days
- •15.Patient with history or current signs and symptoms suggestive of renal impairment (e.g., puffiness of face, pedal oedema, ascites, abnormal urine output etc.)
- •16.Patient with history or current signs and symptoms suggestive of hepatic impairment (e.g., icterus, anemia, ascites, pain in abdomen, abnormal internal bleeding etc.)
- •17.Patient with history or current serious underlying disease like but not limited to epilepsy, congenital disorder, metabolic disorder, cardiovascular disease, hepatic disorder, renal disorder, intestinal perforation or obstruction, congenital gastro-intestinal malformation, genito-urinary disorder etc.
- •18.Concomitant infection which would preclude evaluation of the response of his/her URTI/ LRTI to the study intervention.
- •19.Patient with history of Human Immunodeficiency Virus (HIV) and / or Hepatitis B and/ or Hepatitis C
- •20.Patients with other disease or medication leading to immune-compromised condition
- •21.Patient with history of significant active peptic ulceration
- •22.Patient with history of cancer or undergoing cancer chemo or radiotherapy
- •23.Patient who have participated in another Investigational study within the 3 months prior to enrolment in this study
- •24.Patient with known alcohol or other substance abuse within last one year
- •25.Employee of the Sponsor, Investigator, or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members of the employees of Sponsor or the Investigator.
研究者
相似试验
尚未招募
4 期
A study of Fixed Dose Combination of Tamsulosin and Tadalafil Capsules to check safety and efficacy in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction.CTRI/2022/06/043152Sun Pharma Laboratory Limited SP
已完成
4 期
Safety and Efficacy of Amantadine Tablets for the Treatment of Parkinsons Disease (A disorder of the central nervous system that affects movement, often including tremors) and Drug-induced Extrapyramidal Reactions (involuntary or uncontrollable movements, tremors, muscle contractions) in PatientsCTRI/2023/04/051973Sun Pharma Laboratories Limited (SPLL)163
尚未招募
4 期
Safety and efficacy of Brinzolamide and Timolol eye drops to decrease intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension for whom single drug therapy provides insufficient for intraocular pressure reductioCTRI/2023/05/052720Sun Pharma Laboratories Limited (SPLL)
已完成
4 期
Safety and Efficacy of Cariprazine Capsules in Adult Patients with Schizophrenia (a disorder that affects a persons ability to think, feel and behave clearly) and Acute Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder (mood swings that include emotional highs and lows)CTRI/2023/05/052793Sun Pharmaceutical Industries Limited172
尚未招募
4 期
Safety and Efficacy of Dienogest Tablets in Management of Pelvic Pain Associated with Endometriosis (abnormal tissue growth lying outside uterus)CTRI/2022/04/041959Sun Pharma Laboratories Limited